GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Oculus Innovative Sciences, Inc. (OCLS) [hlAlert]

Rating:
Buy OCLS
down 75.10 %

Oculus Innovative Sciences, Inc. (OCLS) rated Buy with price target $6 by Maxim Group

Posted on: Friday,  Apr 19, 2013  10:25 AM ET by Maxim Group

Maxim Group rated Buy Oculus Innovative Sciences, Inc. (NASDAQ: OCLS) on 04/19/2013, when the stock price was $4.74.
Since then, Oculus Innovative Sciences, Inc. has lost 75.11% as of 09/09/2015's recent price of $1.18.
If you would have followed this Maxim Group's recommendation on OCLS, you would have lost 75.1% of your investment in 873 days.

Oculus Innovative Sciences, Inc. is a biopharmaceutical company that develops, manufactures and markets a family of products, based on its platform technology called Microcyn, intended to help prevent and treat infections in chronic and acute wounds. Microcyn is a non-irritating oxychlorine compound designed to treat a range of pathogens, including viruses, fungi, spores and antibiotic-resistant strains of bacteria, such as Methicillin-resistant Staphylococcus aureus (MRSA), and Vancomycin-resistant Enterococcus (VRE), in wounds. Its device product is cleared for sale in the United States as a 510(k) medical device for wound cleaning, debridement, lubricating, moistening and dressing; is a device under Conformite Europeenne (CE) Mark in Europe; is approved by the State Food and Drug Administration (SFDA), in China as a technology that reduces the propagation of microbes in wounds and creates a moist environment for wound healing, and is approved as a drug in India and Mexico.

At Maxim Group, our vision for equity research is to be a client’s first call for value-added research on companies not widely followed by Wall Street. Maxim’s premier niche is emerging-growth companies in a variety of sectors, including healthcare, technology, retail and others. As strong believers in fundamental research, our analysts utilize a “bottom up” approach to making investment recommendations. We combine rigorous financial analysis of specific companies and industries with due diligence that includes frequent consults with suppliers, customers, competitors and senior management. By applying these skills and techniques, we are able to offer our clients differentiated research.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
4/19/2013 10:25 AM Buy
None
4.74 6.00
as of 12/13/2013
1 Week down  -10.34 %
1 Month up  47.72 %
3 Months up  34.48 %
1 YTD down  -17.72 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy